Arctic Vision, a Shangai, China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, completed an over US$100m Series B financing.
The round was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Dr. Adrian Cheng, renowned entrepreneur from New World Development Group, along with existing investors Nan Fung Life Sciences, Pivotal bioVenture Partners China and Morningside Ventures.
The proceeds will continue to support the progress of Arctic Vision’s pipeline, including clinical developments, registrational activities, and commercialization; as well as the establishment of in-house R&D capabilities; business development, and organizational growth.
Led by Dr. Eddy Wu, Founder, Chief Executive Officer and Board Director, Arctic Vision is a clinical stage specialty ophthalmology company with a portfolio of three late-stage in-licensed products including
- ARVN001 for uveitic macular edema (UME),
- ARVN002 for pediatric progressive myopia, and
- ARVN003 for presbyopia.